Selected Engagements · 30 Years

Proof, not promises.

Each one traces the same pattern: find where commercial value is trapped, build the strategy to unlock it, and execute through partnerships, capital, and teams.


01

FOOD INGREDIENTS · BIOTECHNOLOGY

Spinning a food-tech company out of a biotechnology platform

Smallfood, Inc. (spin-off from Synthetic Genomics) - Chief Business Officer

Proprietary technology with real promise as a food-ingredient platform sat trapped inside a biotech parent whose commercial focus was elsewhere. The work: carve the IP out into a standalone company, capitalize it, build an executive team from scratch, and prove commercial demand - all in parallel, against one unified commercial story.

IP spun out & capitalized as a standalone food-tech company+$27M in supply-agreement commitmentsExecutive team & governance built

The deal didn't close on a single pitch. It closed because investors, customers, and a new executive team were all moving down their tracks at once - against one story.

02

FUNCTIONAL FOOD INGREDIENTS · OMEGA-3

Doubling food sales in three years at Ocean Nutrition Canada

Ocean Nutrition Canada (acquired by DSM, 2012) - Director, North America Food Ingredients

An established ingredient business plateaued at commodity-level margins. The opportunity wasn't to sell more of the same - it was to shift the mix toward higher-value, branded applications inside consumer packaged goods, and set a performance culture where results, not activity, drove the metrics.

total food sales in three yearsValue-added volume +82%Multiple CPG co-branding deals signedPositioned as a key asset in the DSM acquisition

Selected as one of five Matrix Team Leaders to align R&D, regulatory, sales, and marketing that had run in parallel before.

03

VEGETABLE OILS · AGRICULTURAL COMMODITIES

Turning a commodity into a brand at Cargill

Cargill, Inc. - Regional Account Manager (Gainesville, GA); prior Commercial Manager & Commodity Merchant

Vegetable oil sold into industrial channels was, by definition, commodity business - priced off the board, sold by the truckload, margins compressed by everyone doing exactly the same thing. The conventional playbook fought for share on price. I took the opposite approach: stop selling the commodity as a commodity.

Net margin +500% in the branded channelGross profit margin up 51% over five yearsHighest per-pound net margin in the SoutheastSold 675M+ pounds of vegetable oil

The category had decided it was a commodity. The customers hadn't - they just hadn't been offered anything else.

04

B2C CONSUMER BRANDS · B2B GLOBAL FOOD MANUFACTURING

Bringing two international businesses into the U.S. market

Strategia3, LLC - Founder

Two international companies wanted to enter the U.S. - each with a strong home-market foundation but none of the U.S. infrastructure to land here: product strategy, advisory bench, manufacturing relationships, or funding. They needed an operator on the ground to build all of it in parallel.

Both companies established in the U.S.15 SKUs launched in six months (B2C)B2B product strategy aimed at global manufacturersManufacturing, advisory & funding secured

Most market-entry work delivers a plan and stops. This delivered the plan, the team, the factory, the money - and products on shelves in six months.

05

FUNCTIONAL MUSHROOMS · NUTRACEUTICAL BIOACTIVES

Finding a bioactives business hidden inside a mushroom producer

Strategic Review & Repositioning

The company was selling premium mushrooms as a powder - a commodity, priced against far larger growers and overseas suppliers in a race to the bottom. But the real asset was never the powder. A proprietary genetics platform and a clinical-and-analytical lab capability sat underused, with no commercial story attached. My read: stop being a mushroom producer and become a science-based bioactives company - extracting high-value compounds, starting with a natural caffeine alternative, for the fast-growing functional-beverage and premium pet-food markets.

Repositioned from commodity powder to science-based bioactivesSurfaced a natural caffeine alternative from existing geneticsTargeted a market projected at $750M–$1.1B by 2030A Fortune 500 ingredient supplier requested samples

The company had decided it was a mushroom-powder business. Its own genetics said otherwise - the premium was sitting in their lab the whole time.